These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29080240)

  • 41. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
    Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
    Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
    Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
    Sharma S; Ahmad M; Bhat JA; Kumar A; Kumar M; Zargar MA; Hamid A; Shah BA
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4729-4734. PubMed ID: 25176189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
    Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
    Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
    J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and biological activity of hydroxamic tertiary amines as histone deacetylase inhibitors.
    Terracciano S; Chini MG; Riccio R; Bruno I; Bifulco G
    ChemMedChem; 2012 Apr; 7(4):694-702. PubMed ID: 22278987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, Synthesis and Evaluation of Novel 3/4-((Substituted benzamidophenoxy) methyl)-N-hydroxybenzamides/propenamides as Histone Deacetylase Inhibitors and Antitumor Agents.
    Anh DT; Thuan NT; Hai PT; Huong LT; Yen NTK; Han BW; Park EJ; Choi YJ; Kang JS; Hue VTM; Han SB; Nam NH
    Anticancer Agents Med Chem; 2019; 19(4):546-556. PubMed ID: 30426904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors.
    Zhou H; Qi Z; Liu D; Xue X; Wang C
    Chembiochem; 2023 Sep; 24(18):e202300238. PubMed ID: 37366008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
    Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
    Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
    Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
    Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
    Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
    Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
    Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
    Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
    ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
    Zhu C; Liu M; Yuan Y; Chen H; Wu L; Cong Z; Zhao Q; Ding H
    Bioorg Med Chem Lett; 2022 Sep; 72():128846. PubMed ID: 35697181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.